Profile banner
David Berry

David Berry

Serial biotech entrepreneur, company builder, MD PhD, investor

Boston/Cambridge, Massachusetts
valohealth+2
Joined October 2025
Favicon imageaverincapital.com
Favicon imageflagshippioneering.com
Favicon imageaxcellahealth.com
Favicon imagelinkedin.com
Favicon imagex.com

Network

23.7K connections
💰
Healthcare Investors
💊
Biopharma Executives
🌱
Biotech Venture Founders
🧭
Strategic Advisors
📈
Alternative Investments
🤖
Digital Health AI Leaders
⚓
Flagship Pioneering Network

Summary

Serial company creator and builder in biotech and sustainability: Berry has co-founded and helped scale many Flagship-originated ventures (Valo Health, Seres Therapeutics, Indigo, Joule, Evelo, Omega and others). He combines idea-generation, technical depth, and early operational leadership to move platform science toward companies and financings. wikipedia+2
Scientist-entrepreneur with deep technical credentials: trained as an M.D./Ph.D. (Harvard Medical School; MIT Biological Engineering) and recognized for graduate research (dFGF2/heparin work) and invention (Lemelson-MIT prize, 2007 TR35 Innovator). This technical foundation informs his ability to conceive platform technologies and translate them into companies. mit+2
Investor and ecosystem leader: long tenure as a General Partner at Flagship Pioneering (company creation engine) and now co-founder/managing partner at Averin, demonstrating a shift from in‑firm company creation to forming an independent investment platform focused on health and technology-enabled drug development. flagshippioneering+2
Board, civic, and arts engagement: in addition to company boards, Berry participates in educational and cultural institutions (Trustee/Advisory Trustee at Hackley School, past service with Boston Philharmonic and Juventas), and is a recognized participant in global forums (UN SDSN Leadership Council; World Economic Forum Young Global Leader). hackleyschool+2

Work

Education

Projects

Writing

dFGF2 and heparin-related biomedical research (PhD era work)

January 1, 2005

Academic research during MIT graduate work that produced engineered growth-factor / heparin-related approaches (including dimeric FGF2) with applications to stroke recovery and cancer treatment.

Favicon imagelemelson.mit.edu

Public-facing leadership & opinion pieces (Flagship/Valo interviews and talks)

Numerous talks, interviews and thought-leadership pieces about company creation, AI & data in drug discovery, and entrepreneurship (e.g., Flagship CEO Chat, Valo keynote appearances).

Favicon imageflagshippioneering.com

Hobbies

Active supporter / board involvement in classical music and music ensembles (Boston Philharmonic, Juventas New Music Ensemble). wikipedia

Engaged in education philanthropy and school governance (Trustee / Advisory Trustee at Hackley School). hackleyschool